Novartis enlists transatlantic startup to discover new protein degraders in $1.3B+ deal
With NIBR chief Jay Bradner serving as the in-house expert on protein degradation, Novartis has its standards for the technology. A small transatlantic startup is clearly ready to meet them.
Dunad, a new player that emerged in the field in March, has scored a partnership with Novartis to develop what it calls next-generation targeted protein-degrading small molecule drugs. To kick things off, it’s getting $24 million in an upfront and equity investment — plus “significant research funding.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.